Sodium-glucose cotransporter-2 (SGLT2) inhibitors are a new type of drug that can treat diabetes.
But in a recent study from FDA, scientists found that the drugs could lead to a type of infection in the body, including external genitalia, perineum, and perianal region.
The infection was called Fournier gangrene.
In the study, the team examined the health risks of SGLT2 inhibitors and other diabetes drugs, including metformin, insulin glargine, short-acting insulin, sitagliptin plus metformin, and dulaglutide.
They found 55 cases of this infection in diabetic patients using SGLT2 inhibitors between 1 March 2013 and 31 January 2019.
The patients ranged in age from 33 to 87 years. Among them, 39 were men, and 16 were women.
The team found that the onset of infections ranged from 5 days to 49 months after the patients used SGLT2 inhibitors.
These people also experienced several other diabetic complications, including diabetic ketoacidosis, sepsis, and kidney injury.
On the contrary, only 19 cases of infection in patients using other diabetes drugs between 1984 and 31 January 2019.
The team says that the infection is a newly identified safety concern in diabetic patients receiving SGLT2 inhibitors.
Doctors who prescribe this type of drug should be aware of this possible complication and try to detect it in its early stages.
If you care about diabetes, please read studies about what you need to know about diabetes drug metformin, and people with diabetes should consider taking this vitamin.
If you care about diabetes, please read studies that Mediterranean diet could help reduce the diabetes risk by 30%, and heavy cannabis use may decrease the incidence of diabetes.
The study was published in the Annals of Internal Medicine and conducted by Susan J. Bersoff-Matcha et al.
Copyright © 2022 Knowridge Science Report. All rights reserved.